Lynx1 Capital Management as of June 30, 2025
Portfolio Holdings for Lynx1 Capital Management
Lynx1 Capital Management holds 15 positions in its portfolio as reported in the June 2025 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Merus N V (MRUS) | 23.8 | $83M | 1.6M | 52.60 | |
| Gh Research Ordinary Shares (GHRS) | 23.8 | $82M | 6.7M | 12.19 | |
| Stoke Therapeutics (STOK) | 17.7 | $61M | 5.4M | 11.35 | |
| Protagonist Therapeutics (PTGX) | 11.7 | $41M | 733k | 55.27 | |
| Cullinan Oncology (CGEM) | 9.6 | $33M | 4.4M | 7.53 | |
| Allogene Therapeutics (ALLO) | 3.6 | $13M | 11M | 1.13 | |
| Tscan Therapeutics (TCRX) | 3.3 | $11M | 7.9M | 1.45 | |
| C4 Therapeutics Com Stk (CCCC) | 2.9 | $10M | 7.1M | 1.43 | |
| Precision Biosciences Com New (DTIL) | 1.3 | $4.4M | 1.0M | 4.20 | |
| Passage Bio | 1.1 | $3.7M | 9.3M | 0.40 | |
| Upstream Bio (UPB) | 0.7 | $2.4M | 219k | 10.98 | |
| Ibio Com New (IBIO) | 0.3 | $1.2M | 1.5M | 0.76 | |
| Neuphoria Therapeutics (NEUP) | 0.1 | $325k | 46k | 7.10 | |
| Design Therapeutics (DSGN) | 0.1 | $222k | 66k | 3.37 | |
| Assembly Biosciences Com New (ASMB) | 0.1 | $188k | 10k | 18.12 |
